The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
From bench to bedside and back: prognostic groups of Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial—A GISCAD study.
 
Eleonora Lai
Consulting or Advisory Role - AstraZeneca; MSD/AstraZeneca
 
Sabina Murgioni
No Relationships to Disclose
 
Pina Ziranu
No Relationships to Disclose
 
Giuseppe Aprile
Consulting or Advisory Role - Amgen; Baxter; Bristol-Myers Squibb/Celgene; Lilly; Merck; SERVIER
 
Alberto Zaniboni
No Relationships to Disclose
 
Andrea Pretta
No Relationships to Disclose
 
Floriana Nappo
No Relationships to Disclose
 
Stefania Mosconi
No Relationships to Disclose
 
Alessandro Bittoni
No Relationships to Disclose
 
Michela Squadroni
No Relationships to Disclose
 
Alessandro Cappetta
No Relationships to Disclose
 
Francesca Daniel
No Relationships to Disclose
 
Luigi Mascia
No Relationships to Disclose
 
Gerardo Rosati
No Relationships to Disclose
 
M. Giulia Zampino
No Relationships to Disclose
 
Fabio Gelsomino
No Relationships to Disclose
 
Francesca Simionato
No Relationships to Disclose
 
Michela Rofei
No Relationships to Disclose
 
Nicoletta Pella
No Relationships to Disclose
 
Mario Scartozzi
Consulting or Advisory Role - Amgen; Bayer; Eisai; Merck; MSD; Sanofi
Speakers' Bureau - Amgen; Bayer; Eisai; Merck; MSD; Sanofi